Immutep (IMMP) Price & Analysis

Compare

678 Followers

IMMP Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.32 - $2.72

Previous CloseN/A

Volume50.42K

Average Volume (3M)72.56K

Market Cap

$258.60M

Enterprise Value$124.09M

Total Cash (Recent Filing)$159.26M

Total Debt (Recent Filing)$1.68M

Price to Earnings (P/E)―

Beta1.24

Next Earnings

Aug 27, 2025

EPS Estimate

-0.16

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.10

Shares Outstanding146,786,480

10 Day Avg. Volume86,253

30 Day Avg. Volume72,563

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.48

Enterprise Value/Revenue25.44

Enterprise Value/Gross Profit-2.99

Enterprise Value/Ebitda-2.55

Forecast

1Y Price Target

$6.75

Price Target Upside277.09% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessThe P2b TACTI-003 trial showed a 17.6-month median overall survival for the efti + Keytruda combination, comparing favorably to historical benchmarks, indicating strong clinical performance.

PartnershipsImmutep is collaborating with Merck for the ongoing P3 trial in Eftilagimod alpha, which could enhance development and market potential.

Regulatory ApprovalThe FDA acknowledged the therapeutic potential of the efti + Keytruda combination in an underserved patient population with no chemo-free option available, suggesting a promising regulatory outlook.

Bears Say

Financial ConstraintsDespite having a strong cash position, the company must manage resources carefully to ensure funding through the end of 2026 amidst ongoing trials and developments.

Market CompetitionThe competitive landscape in cancer treatment may pose challenges for Immutep's efti + Keytruda combination to establish a foothold as a preferred treatment.

Regulatory ChallengesUnder FDA’s Project FrontRunner, the need for either a randomized registrational trial or a smaller single-arm study could present potential regulatory hurdles.

Immutep News

Immutep receives FDA feedback on clinical development of eftilagimod alfa

Immutep (IMMP) received positive and constructive feedback from the US Food and Drug Administration, regarding future clinical development...

6d ago

IMMP

Immutep reports Q4 cash receipts from customers A$6,000

During the quarter, Immutep (IMMP) continued to exercise prudent cash management as it advanced its clinical trial programs...

12d ago

IMMP

Immutep Gains FDA Support for Eftilagimod Alfa in Cancer Treatment

Immutep ( ($IMMP) ) has provided an announcement. On August 5, 2025, Immutep Limited announced that it received...

4d ago

IMMP

Immutep’s Strategic Advances and Promising Clinical Data Drive Buy Rating

Maxim Group analyst Jason McCarthy maintained a Buy rating on Immutep yesterday and set a price target of...

5d ago

IMMP

Immutep Reports Significant Progress in Cancer and Autoimmune Trials

An announcement from Immutep ( ($IMMP) ) is now available. Immutep Limited has announced significant progress in its...

11d ago

IMMP

Immutep Reports Promising Phase I Results for IMP761 in Autoimmune Diseases

Immutep ( ($IMMP) ) just unveiled an announcement. On June 23, 2025, Immutep announced positive results from its...

2M ago

IMMP

Immutep announces initial efficacy data from Phase I study of IMP761

Immutep (IMMP) announces initial efficacy data and continued safety data from the placebo-controlled, double-blind first-in-human Phase I study...

2M ago

IMMP

Immutep’s Efti Combination Therapy Shows Promising Results in Soft Tissue Sarcoma Trial

The latest announcement is out from Immutep ( ($IMMP) ). Immutep Limited announced on May 26, 2025, that...

3M ago

IMMP

Immutep announces EFTISARC-NEO Phase II trial met primary endpoint

Immutep (IMMP) announces the investigator-initiated EFTISARC-NEO Phase II trial evaluating eftilagimod alfa with radiotherapy plus KEYTRUDA in the...

3M ago

IMMP

Immutep’s Promising Phase 1 INSIGHT-003 Results Drive Buy Rating

Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Immutep (IMMP – Research Report) and keeping...

3M ago

IMMP

Immutep’s Efti Combination Shows Promising Results in Lung Cancer Trial

Immutep ( ($IMMP) ) has shared an update. On May 15, 2025, Immutep announced promising results from its...

3M ago

IMMP

Immutep announces response rates from INSIGHT-003 trial

Immutep (IMMP) Limited announces that a 60.8% response rate and 90.2% disease control rate, according to RECIST1.1, has...

3M ago

IMMP

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

3M ago

MRK

ATHE

Immutep’s Promising Phase 2b Results and Strong Financial Position Justify Buy Rating

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Immutep (IMMP – Research Report). The...

3M ago

IMMP

IMMP FAQ

What was Immutep’s price range in the past 12 months?

Immutep lowest stock price was $1.32 and its highest was $2.72 in the past 12 months.

What is Immutep’s market cap?

Immutep’s market cap is $258.60M.

When is Immutep’s upcoming earnings report date?

Immutep’s upcoming earnings report date is Aug 27, 2025 which is in 16 days.

How were Immutep’s earnings last quarter?

Immutep released its earnings results on Feb 26, 2025. The company reported -$0.096 earnings per share for the quarter, beating the consensus estimate of -$0.136 by $0.04.

Is Immutep overvalued?

According to Wall Street analysts Immutep’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Immutep pay dividends?

Immutep does not currently pay dividends.

What is Immutep’s EPS estimate?

Immutep’s EPS estimate is -0.16.

How many shares outstanding does Immutep have?

Immutep has 146,786,480 shares outstanding.

What happened to Immutep’s price movement after its last earnings report?

Immutep reported an EPS of -$0.096 in its last earnings report, beating expectations of -$0.136. Following the earnings report the stock price went up 1.064%.

Which hedge fund is a major shareholder of Immutep?

Currently, no hedge funds are holding shares in IMMP

Immutep Stock Smart Score

Underperform

Fundamentals

Return on Equity

-31.16%

Trailing 12-Months

Asset Growth

33.65%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Immutep

Immutep (IMMP) is a biotechnology company focused on developing novel immunotherapy treatments for cancer and autoimmune diseases. The company is a leader in the development of LAG-3-related immunotherapeutics and is actively involved in research and development to create innovative therapies that enhance the immune system's ability to fight diseases. Immutep's pipeline includes several promising product candidates at various stages of clinical development, targeting various cancer types and autoimmune conditions.

Immutep (IMMP) Earnings & Revenues

Historic Earnings Reports

IMMP Stock 12 Month Forecast

Average Price Target

$6.75

▲(277.09% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.72,2.5107692307692306,3.3015384615384615,4.092307692307692,4.883076923076922,5.673846153846153,6.464615384615384,7.255384615384615,8.046153846153846,8.836923076923076,9.627692307692307,10.418461538461537,11.20923076923077,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.72,2.106923076923077,2.493846153846154,2.8807692307692307,3.2676923076923075,3.6546153846153846,4.041538461538462,4.428461538461538,4.815384615384615,5.202307692307692,5.5892307692307694,5.976153846153846,6.363076923076923,{"y":6.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.72,1.7030769230769232,1.6861538461538461,1.6692307692307693,1.6523076923076923,1.6353846153846154,1.6184615384615384,1.6015384615384616,1.5846153846153845,1.5676923076923077,1.5507692307692307,1.5338461538461539,1.5169230769230768,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.98,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.63,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.15,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.05,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.93,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.77,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.67,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.86,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.65,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >